Biomatics Capital Partners, a Seattle, WA-based venture capital firm investing in innovation at the intersection of health care and technology, closed its first fund, at $200m.
Investors include a mix of family offices, institutions and individuals.
Led by Managing Directors Boris Nikolic, M.D. and Julie Sunderland, who have invested together in emerging technology, health care and life science ventures since 2010, Biomatics focuses on advancing academic research and early-stage health care innovation to commercialization, with investments concentrated in areas of genomics, digital health and data-driven health care technologies.
The firm estimates that it will invest in 15-20 companies through this fund, acting as Series A lead investor in a majority of the deals. Initial investments typically range from $5m to $10m, with up to $20m over the life of the investment.
Once invested, MDs take an active role with portfolio companies, supporting startups with hiring, intellectual property, regulatory issues and exit strategy.
Biomatics’ current portfolio includes:
– AiCure (medication adherence powered by artificial intelligence),
– Aledade (data-driven business model for accountable health care),
– BlackThorn Therapeutics (informatics-driven drug discovery),
– Blue Talon (enterprise-level data security for health care),
– Denali Therapeutics (next-gen therapeutics for neurodegenerative diseases),
– GRAIL (genomics-based cancer screening),
– Omniome (low-cost DNA sequencing platform) and
– Twist Bioscience (synthetic DNA).